替格瑞洛对NSTE-ACS合并T2DM患者早期PCI围术期唾液酸水平及心功能的影响

doi:10.3969/j.issn.1671-7171.2022.08.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1117 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effects of ticagrelor on the level of sialic acid (SA) and heart function of non-ST-elevation acute coronary syndrome (NSTE-ACS) complicated with type 2 diabetic mellitus (T2DM) patients while receiving perioperative-early percutaneous coronary intervention (PCI). 【Methods】A total of 200 T2DM diabetic patients complicated with non-ST-elevation acute coronary syndrome who were hospitalized and underwent early PCI in Hunan Province's Brain Hospital and People's Hospital of Leiyang from January 2019 to July 2021 were recruited in the study. They were divided into two groups in random,the observation group(with ticagrelor,n=100)and the control group(with clopidogrel,n=100).The serum SA levels were compared between the two groups before operation and postoperation (6 h,24 h,3 d and 7 d). The left ventricular ejection fraction (LVEF),left ventricular end-diastolic diameter(LVDd) and left ventricular end-diastolic volume(LVEDV)were compared between the two groups before operation and 1 week after surgery. 【Results】The levels of SA in two groups were not significantly different before operation(P>0.05),while postoperative 6 h,the levels were higher than those before operation(P<0.05),then SA levels at 24 h,3 d and 7 d after operation decreased in both groups. The difference was statistically significant (P<0.05). The levels of serum SA in the observation group at 6 h,24 h,3 d,and 7 d after operation were lower than those in the control group,the differences were statistically significant (P<0.05). On the 7th day after operation,the LVDd and LVEDV of the two groups were lower than those before operation,while the LVEF was higher than that before operation. The difference between the observation group and the control group was statistically significant (P<0.05).【Conclusion】Both ticagrelor and clopidogrel can effectively down-regulate SA and improve heart function of NSTE-TCS patients complicated with T2DM after PCI.The efficacy of ticagrelor was better than clopidogrel.

Key words： Platelet Aggregation Inhibitors/TU Acute Coronary Syndrome/CO Diabetes Mellitus, Type 2/CO Heart Function Tests

Received: 29 August 2021

PACS:

R543.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.08.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I8/1124

[1] REN J,MA R,ZHANG Z B. Effects of microRNA-330 on vulnerable atherosclerotic plaques formation and vascular endothelial cell proliferation through the WNT signaling pathway in acute coronary syndrome[J].J Cell Biochem,2018,119(6):4514-4527.
[2] 鲜彤章,郭立新.糖尿病大血管病变研究进展及展望[J].药品评价,2009,6(4):126-128.
[3] ISRAR M,GUL C,REHMAN A U. Relationship of lipids,C-reactive protein and sialic acid in the healthy individuals[J].J Ayub Med Coll Abbottabad,2018,30(2):213-216.
[4] WHITE E J,GYULAY G,LHOTÁK Š. Sialidase down-regulation reduces non-HDL cholesterol,inhibits leukocyte transmigration,and attenuates atherosclerosis in ApoE knockout mice[J].J Biol Chem,2018,293(38):14689-14706.
[5] LIN Y,DAN H,LU J. Overexpression of microRNA-136-3p alleviates myocardial injury in coronary artery disease via the Rho A/ROCK signaling pathway[J].Kidney Blood Press Res,2020,45(3):477-496.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[8] LONDREGAN A T,WEI L,XIAO J. Small molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors:hit to lead optimization of systemic agents[J].J Med Chem,2018,61(13):5704-5718.
[9] 钟晓鸣,李彦明,李娟.经皮冠状动脉介入对急性冠脉综合征患者血清hs-CRP水平变化及预后的影响[J].中国实验诊断学,2018,22(7):1142-1145.
[10] 程诚,王鑫.冠心病合并2型糖尿病患者PCI术后支架内再狭窄危险因素分析[J].中国循证心血管医学杂志,2018,10(2):196-198.
[11] 张涛,蓝县武,麦鸿成.替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死行介入治疗患者安全性及有效性评估的回顾性分析[J].暨南大学学报(自然科学与医学版),2018,39(1):73-79.
[12] 李晓红,杨明,韩凌.替格瑞洛及氯吡格雷对急性冠脉综合征介入治疗后的疗效比较[J].武警医学,2018,29(1):14-16.
[13] YANG Y,LEWIS J P,HULOT J S. The pharmacogenetic control of antiplatelet response:candidate genes and CYP2C19[J].Expert Opin Drug Metab Toxicol,2015,11(10):1599-1617.
[14] STORELLI F,DAALI Y,DESMEULES J. Pharmacogenomics of oral antithrombotic drugs[J].Curr Pharm Des,2016,22(13):1933-1949.